GlassScriptPhysician profile
Seyedehsan Navabi
NPI 1801229109
$279,083.47
in general payments reported to CMS, 2019-2025
30 companies · $144K in 2025
The $144K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.36 · 2021: $1,977 · 2022: $6,771 · 2023: $35K · 2024: $91K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $189K · Travel and Lodging: $44K · Consulting Fee: $27K · Food and Beverage: $10K · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $189,081.86 |
| Travel and Lodging | $43,595.29 |
| Consulting Fee | $27,221.25 |
| Food and Beverage | $10,276.24 |
| Education | $148.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $120,504.31 | 2021-2025 | Omvoh, Ebglyss, Zepbound |
| Janssen Biotech, INC. | $86,320.46 | 2022-2025 | Tremfya, Stelara, Simponi |
| Eli Lilly and Company | $38,229.07 | 2022-2025 | Omvoh |
| Pfizer INC. | $27,358.37 | 2022-2025 | |
| Celltrion USA INC. | $3,957.40 | 2024-2025 | Vegzelma, Zymfentra |
| Abbvie INC. | $950.33 | 2023-2025 | |
| Celgene Corporation | $302.73 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $262.44 | 2023-2025 | Entyvio |
| Qol Medical, LLC | $176.61 | 2023-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $122.47 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.23 | 2023 | Zeposia |
| Aimmune Therapeutics, INC. | $100.06 | 2024-2025 | Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.48 | 2023 | Xifaxan |
| Medtronic, INC. | $85.30 | 2023 | Bravo |
| Phathom Pharmaceuticals, INC. | $71.50 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $70.12 | 2021-2023 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $67.93 | 2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $48.96 | 2023 | |
| Conmed Corporation | $47.33 | 2021 | |
| Ferring Pharmaceuticals INC. | $41.60 | 2023-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $29.73 | 2025 | Iqirvo |
| Astellas Pharma US INC | $28.04 | 2024 | Xospata |
| Braintree Laboratories, INC. | $26.28 | 2024 | Sutab, Suflave |
| Laborie Medical Technologies Corp. | $21.99 | 2023 | |
| Madrigal Pharmaceuticals | $20.08 | 2024 | Resmetirom |
| Novo Nordisk INC | $19.29 | 2025 | Wegovy |
| Dynavax Technologies Corporation | $13.36 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seyedehsan Navabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.